163 related articles for article (PubMed ID: 8686122)
1. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer].
Stepanov VN; Goriunov VG; Chechenin MG; Sivkov AV; Gubdurakhmanov II
Urol Nefrol (Mosk); 1995; (6):33-6. PubMed ID: 8686122
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer].
Gurina LI; Iudin SV; Rusakov IG; Bystrov AA
Urologiia; 2003; (4):25-30. PubMed ID: 12942722
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
5. [Drug treatment of prostatic carcinoma].
Kool JC
Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808
[No Abstract] [Full Text] [Related]
6. [Therapy of prostatic cancer with cyproterone acetate].
Maier U
Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
9. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
10. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
[TBL] [Abstract][Full Text] [Related]
11. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
12. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
13. Androcur 50 in the treatment of prostatic carcinoma. Belgian multicentric study with the participation of 30 urologists.
Peetermans C; Roux E
Acta Urol Belg; 1994 Apr; 62(1):77-82. PubMed ID: 8197933
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
16. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
17. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
19. [The treatment of prostatic carcinoma with cyproterone acetate].
Tsvetkov M; Mladenov D; Kumanov Kh
Khirurgiia (Sofiia); 1996; 49(1):12-5. PubMed ID: 8975080
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of virginal prostatic cancer with cyproterone acetate].
Maier U
Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
